Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

• Source: Shutterstock

When it comes to immunotherapy, multiple myeloma has been a relative latecomer. The first immunotherapy for the second most common blood cancer, Bristol Myers Squibb Company and 2seventy Bio, Inc.’s BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), received US Food and Drug Administration approval in 2021, seven years after the introduction of PD-1 checkpoint inhibitors. But now the immunotherapy field for multiple myeloma is exploding, with a plethora of agents targeting BCMA along with more novel targets like GPRC5D and FcRH5. Outside of immunotherapy, BMS’s cereblon E3 ligase modulator (CELMoD) class is in Phase III development.

The range of new therapies coming down the pike means more options than ever for multiple myeloma patients. But the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Market Snapshot

Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

 
• By Alaric DeArment

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves

 
• By Alaric DeArment

KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.

IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs

 
• By Mandy Jackson

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.

IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands

 
• By Mandy Jackson

Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.